European Biotechs benefit from public equity offerings in the U.S.
Without a doubt, our analysis confirms the hypothesis that U.S. stock exchanges are more attractive for Biotech companies seeking public equity due to a larger capital environment with a higher number of investors and research analysts. The … Read more